Spectral announces new findings on the effectiveness of EAA(TM)/Toraymyxin(TM) at the 28th International Symposium on ... (PR Newswire via Yahoo! Finance)
Spectral Diagnostics Inc. today announced that new findings were presented showing a mortality reduction in endotoxemic patients through the combined use of Spectral's EAA Endotoxin Activity Assay, the only FDA cleared diagnostic for the measurement of endotoxin, and Toray Medical Company's Toraymyxin column, a blood purification device that absorbs endotoxin from the bloodstream.

Abiomed Receives Conditional FDA Approval for Impella 2.5 Study for Acute Myocardial Infarction (AMI) Patients (Business Wire via Yahoo! Finance)
DANVERS, Mass.----Abiomed, Inc. announced today that it has received conditional approval from the U.S. Food and Drug Administration to begin its Impella 2.5 Circulatory Support System study in the United States under an investigational device exemption for hemodynamically unstable patients undergoing a percutaneous coronary intervention procedure due to acute myocardial infarction , commonly ...

Hawthorn Pharmaceuticals, Inc. Receives FDA Approval On Granisol Oral Solution (Medical News Today)
Hawthorn Pharmaceuticals, Inc. announced the US Food and Drug Administration (FDA) approval of the company's Granisol (granisetron HCl) Oral Solution. Granisol is an oral solution for the prevention of nausea and vomiting associated with cancer therapy. Granisol is the AA-rated equivalent of Roche's Kytril Oral Solution.